Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2) (PerCellVac2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02808364|
Recruitment Status : Active, not recruiting
First Posted : June 21, 2016
Last Update Posted : June 7, 2019
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma||Biological: Personalized cellular vaccine||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Personalized Cellular Vaccine Therapy in Treating Patients With Recurrent Glioblastoma (PerCellVac2)|
|Study Start Date :||June 2016|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||September 2020|
Experimental: Personalized cellular vaccine
Subjects will undergo tumor resection. They will receive biweekly cellular vaccines consisting of mRNA tumor antigen pulsed autologous DCs.
Biological: Personalized cellular vaccine
Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
Other Name: Tumor antigen pulsed DC autologous cellular vaccine
- Incidence of treatment-emergent adverse events and severe adverse events (safety and tolerability) [ Time Frame: 3 years since the beginning of the first vaccine ]Incidence of adverse events and severe adverse events to measure safety and tolerability of mRNA-TAA pulsed autologous DC, allogeneic PBMCs and autologous tumor cellular vaccines.
- Antitumor antigen specific T cell response [ Time Frame: 4 weeks after the last vaccine ]The frequency of the peripheral CD8+ and CD4+ T cell response to the vaccine will be measured.
- Progression-free survival [ Time Frame: 12 months since the beginning of the first vaccine ]Progression-free survival will be monitored for 1 year.
- Overall survival [ Time Frame: 3 years since the beginning of the first vaccine ]Overall survival will be monitored for 3 years.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02808364
|Guangdong 999 Brain Hospital|
|Guangzhou, Guangdong, China|
|Principal Investigator:||Jian Zhang, M.D.||Guangdong 999 Brain Hospital|